文献速递脑血管病神经重症与神经感染

氨甲环酸预防脑出血血肿扩大:斑点征阳性与阴性患者比较

Tranexamic Acid for Prevention of Hematoma Expansion in Intracerebral Hemorrhage Patients With or Without Spot Sign.
PubMed 文献 · Stroke · 2021-05-18

本研究为TICH-2试验的亚组分析,纳入254例有影像可判定斑点征状态的急性脑出血患者,其中64例(25.2%)斑点征阳性。比较氨甲环酸与安慰剂对第2天血肿体积的影响,斑点征阳性者调整后绝对体积差异为3.7%(95%CI -12.8%至23.4%),阴性者为1.7%(95%CI -8.4%至12.8%),异质性P=0.85,提示斑点征状态不改变氨甲环酸的治疗效应。

要点

  • 斑点征状态未显著改变氨甲环酸对血肿扩大的治疗效果(异质性P=0.85)。
  • 斑点征阳性与阴性患者中,氨甲环酸对显著血肿进展的OR分别为0.85和0.77,异质性P=0.88。
  • 结果可能受低统计效能和治疗延迟影响,需谨慎解读。

核心结论

  • TICH-2试验数据不支持入院时斑点征状态会改变氨甲环酸与安慰剂对急性脑出血患者的治疗效果。
  • 结果可能受低统计效能及治疗延迟影响。

研究设计与样本

  • TICH-2试验为随机、安慰剂对照临床试验,纳入症状发作8小时内急性住院脑出血患者。
  • 参与者按1:1随机接受静脉氨甲环酸2克或匹配安慰剂。
  • 本亚组分析纳入主试验中影像可判定斑点征状态的全部参与者,共254例(占2325例的10.9%)。
  • 其中斑点征阳性64例(25.2%)。
  • 从症状发作到给药的中位时间为225.0分钟(四分位距169.0至310.0分钟)。

主要发现

  • 斑点征阳性者中,氨甲环酸组与安慰剂组第2天绝对血肿体积的调整后百分比差异为3.7%(95%CI -12.8%至23.4%)。
  • 斑点征阴性者中,相应差异为1.7%(95%CI -8.4%至12.8%)。
  • 两组间异质性P=0.85。
  • 显著血肿进展(二分类复合结局)在斑点征阳性者中的OR为0.85(95%CI 0.29至2.46),阴性者为0.77(95%CI 0.41至1.45),异质性P=0.88。

临床怎么用

  • 对于急性脑出血患者,不应仅依据入院斑点征状态选择是否使用氨甲环酸。
  • 需考虑治疗延迟和统计效能对结果解释的影响。

局限性

  • 仅254例(10.9%)参与者影像可判定斑点征状态,样本量有限。
  • 结果可能受低统计效能影响。
  • 治疗延迟可能影响结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The computed tomography angiography or contrast-enhanced computed tomography based spot sign has been proposed as a biomarker for identifying on-going hematoma expansion in patients with acute intracerebral hemorrhage. We investigated, if spot-sign positive participants benefit more from tranexamic acid versus placebo as compared to spot-sign negative participants. METHODS: TICH-2 trial (Tranexamic Acid for Hyperacute Primary Intracerebral Haemorrhage) was a randomized, placebo-controlled clinical trial recruiting acutely hospitalized participants with intracerebral hemorrhage within 8 hours after symptom onset. Local investigators randomized participants to 2 grams of intravenous tranexamic acid or matching placebo (1:1). All participants underwent computed tomography scan on admission and on day 2 (24±12 hours) after randomization. In this sub group analysis, we included all participants from the main trial population with imaging allowing adjudication of spot sign status. RESULTS: Of the 2325 TICH-2 participants, 254 (10.9%) had imaging allowing for spot-sign adjudication. Of these participants, 64 (25.2%) were spot-sign positive. Median (interquartile range) time from symptom onset to administration of the intervention was 225.0 (169.0 to 310.0) minutes. The adjusted percent difference in absolute day-2 hematoma volume between participants allocated to tranexamic versus placebo was 3.7% (95% CI, -12.8% to 23.4%) for spot-sign positive and 1.7% (95% CI, -8.4% to 12.8%) for spot-sign negative participants (Pheterogenity=0.85). No difference was observed in significant hematoma progression (dichotomous composite outcome) between participants allocated to tranexamic versus placebo among spot-sign positive (odds ratio, 0.85 [95% CI, 0.29 to 2.46]) and negative (odds ratio, 0.77 [95% CI, 0.41 to 1.45]) participants (Pheterogenity=0.88). CONCLUSIONS: Data from the TICH-2 trial do not support that admission spot sign status modifies the treatment effect of tranexamic acid versus placebo in patients with acute intracerebral hemorrhage. The results might have been affected by low statistical power as well as treatment delay. Registration: URL: http://www.controlled-trials.com; Unique identifier: ISRCTN93732214.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Ovesen C, Jakobsen JC, Gluud C, et al. Tranexamic Acid for Prevention of Hematoma Expansion in Intracerebral Hemorrhage Patients With or Without Spot Sign. Stroke. 2021. PMID: 34000834. doi:10.1161/STROKEAHA.120.032426

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。